ADC Bioanalysis Knowledge Base

AAPS_ADC_WhitePapers

7 min read

AAPS ADC Bioanalysis & Immunogenicity White Papers (2013–2022)

概述 Overview

Industry white papers from the AAPS ADC Working Group (WG) and European Bioanalysis Forum (EBF) represent the authoritative industry consensus on ADC bioanalysis — they predate or supplement regulatory guidances and are routinely cited in FDA/EMA submissions. Unlike regulatory guidances (which are binding), white papers are not mandatory but serve as the interpretive framework regulators use to evaluate ADC bioanalytical packages.

Key documents (in chronological order):

YearAuthorsTitleJournalPMID
2013aGorovits B et al. (AAPS ADC WG)Bioanalysis of antibody-drug conjugates: AAPS ADC Working Group position paperAAPS J23641692
2013bKaur S et al.Bioanalytical assay strategies for the development of ADC biotherapeuticsBioanalysis23289473
2014Shankar G et al.Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugatesAAPS J23641695
2015Shankar G et al.Immunogenicity of ADCs: bioanalytical methods and monitoring strategyAAPS J25380723
2019EBF ADC teamEBF recommendations on ADC bioanalysisBioanalysis—
2020AAPS/FDA WorkshopUpdated recommendations: ADC bioanalysis workshop reportAAPS J—
2022EBF ADC teamEBF recommendations update: evolving practices in ADC bioanalysisBioanalysis—

核心要点 Key Points

1. Gorovits et al. 2013 — The Foundational Position Paper

Full citation: Gorovits B, Alley SC, Bilic S, et al. “Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper.” AAPS J. 2013;15(2):239-47. DOI: 10.1208/s12248-012-9396-2

Core recommendations (now standard practice, formalized in ICH M10):

Analyte hierarchy established:

Minimum required analytes:
  1. Total antibody (TAb)     → LBA (anti-Fc capture, anti-Fab detect)
  2. Conjugated antibody (cAb)→ LBA (anti-Fc capture, anti-drug detect)
  3. Free payload              → LC-MS/MS

Optional / case-by-case:
  4. Conjugated payload (hybrid LBA-MS)
  5. Catabolites (if active)
  6. Soluble antigen (sTAA)

Platform selection framework:

  • LBA: preferred for TAb and cAb (higher sensitivity; matrix tolerant)
  • LC-MS/MS: preferred for free payload (selectivity; no need for anti-payload antibody)
  • Hybrid LBA-MS: emerging; useful when anti-drug antibodies are unavailable or when DAR-weighted cAb measurement is needed

Non-clinical specific recommendations:

  • Rat plasma: pre-validate with esterase inhibitor (NaF) for linker-containing ester bonds
  • Species selectivity: validate assay in each species matrix used (rat, monkey, human)
  • Sample collection: K₂EDTA, ice, immediate centrifuge; freeze within 1 h

2. Kaur et al. 2013 — Assay Strategy for ADC Programs

Full citation: Kaur S, Xu K, Saad OM, Dere RC, Carrasco-Triguero M. “Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics.” Bioanalysis. 2013;5(2):201-26. DOI: 10.4155/bio.12.299

Key contributions:

Hybrid LBA-LC/MS/MS methodology (first systematic description):

  1. Affinity capture: biotinylated antigen or anti-Fc antibody on streptavidin beads → captures all antibody-containing species
  2. Wash steps to remove matrix proteins
  3. Reduction and alkylation (for site-specific linker analysis) or on-bead protease digestion
  4. LC-MS/MS quantitation of released payload (or signature peptide from antibody)

Advantages demonstrated:

  • Species-independent (no secondary antibody needed)
  • Directly measures payload molecules per antibody (DAR-weighted cAb)
  • More sensitive and specific than ELISA for low payload concentrations

Stability insights:

  • Val-Cit linker ADCs stable in human plasma at 37°C for ≥7 days (cathepsin B inactive at pH 7.4)
  • Disulfide linker ADCs: significant plasma instability in hemolyzed samples (GSH-mediated)
  • Ester/carbonate linkers: rapid hydrolysis in rat plasma (CES activity); NaF additive required

3. Shankar et al. 2014/2015 — ADC Immunogenicity Framework

Full citation (2015): Shankar G, Bhatt S, et al. “Immunogenicity of Antibody Drug Conjugates: Bioanalytical Methods and Monitoring Strategy for a Novel Therapeutic Modality.” AAPS J. 2015;17(1):96-108. DOI: 10.1208/s12248-014-9684-6 (PMID: 25380723)

ADC-specific immunogenicity principles:

1. Risk assessment matrix:

ADC FeatureImmunogenicity Risk Impact
Humanized mAb backboneBaseline low risk from Ab component
High DAR (>4)↑ risk: hydrophobic payload-linker exposed on surface → aggregation
Cleavable linkerPossible anti-linker ADA if linker is immunologically novel
Cytotoxic payload↓ risk: immunosuppressive effect of cytotoxic payload in patients
Novel payload class↑ risk: hapten effect of small molecule → anti-payload ADA

2. Neoepitope ADA — unique to ADCs:

  • Drug-linker moiety conjugated to antibody creates a neoepitope (novel epitope not present on unconjugated antibody)
  • Anti-neoepitope ADA can bind the ADC but not the naked antibody
  • Detection requires assay using the conjugated ADC (not naked mAb) as both capture and detection reagent
  • Characterization: competition with naked mAb vs. drug-linker moiety distinguishes anti-idiotype from anti-drug/anti-linker ADA

3. Recommended ADA assay format for ADCs: ECL bridging assay with:

  • Drug conjugate (full ADC) as capture AND detection arm
  • Acid dissociation pretreatment (pH 3.5, 15–30 min) to improve drug tolerance
  • Positive control: affinity-purified polyclonal anti-ADC antibody or rabbit anti-ADC immunization product
  • Drug tolerance validation: confirm sensitivity with positive control ADA at concentrations expected in post-dose samples

4. AAPS/FDA Workshop 2020 — Updated Consensus

Emerging consensus from the 2020 AAPS/FDA ADC bioanalysis workshop:

New recommendations beyond 2013 papers:

  1. Hybrid LBA-LC/MS/MS is now a validated primary assay for cAb in some programs — not just a supporting tool
  2. Free payload method development: HRMS (high-resolution MS) increasingly used for ultra-potent payloads (PBD, calicheamicin, alpha-amanitin) where conventional MRM sensitivity is insufficient
  3. Catabolite characterization: More emphasis on characterizing the pharmacologically active catabolite spectrum (especially for NCL ADCs like T-DM1)
  4. DAR characterization in clinical samples: Native MS or HIC-MS from immunocaptured ADC in plasma — now feasible as a clinical research tool
  5. Matrix equivalence: Accept human K₂EDTA plasma as default; document any deviation from this with stability data

Evolving areas (not yet fully resolved as of 2020):

  • Standardization of “conjugated payload” vs. “conjugated antibody” as the primary efficacy bioanalytical analyte
  • Regulatory harmonization between FDA and EMA on minimum required analyte panel
  • ISR approach for hybrid LBA-MS assays (no consensus on % or criteria)

5. EBF Recommendations (2019 + 2022)

The European Bioanalysis Forum published ADC-specific recommendations aligning with EMA perspective:

Key EBF positions:

  • Supports tri-analyte approach (TAb + cAb + free payload) — consistent with FDA ADC ClinPharm 2024
  • Endorses hybrid LBA-MS as an equivalent or superior alternative to ELISA for cAb
  • Recommends parallelism testing for all LBA methods at Phase 2 initiation at minimum
  • Emphasis on critical reagent lifecycle management: lot bridging studies, long-term stability of anti-drug antibodies and antigen reagents
  • ADA: acid dissociation standard for all ADC ADA programs; report drug tolerance level explicitly in bioanalytical reports submitted to EMA

常见问题和挑战，具体案例和解决方案

Challenge 1: No Anti-Drug Antibody Available for cAb ELISA Detection

Problem: The payload is a novel small molecule with no commercially available anti-payload antibody, and in-house antibody development has failed. The standard cAb ELISA (anti-Fc capture + anti-drug detection) cannot be implemented.

AAPS WG solution: Use hybrid LBA-LC/MS/MS instead:

  1. Affinity capture using antigen-coated beads or anti-Fc beads → captures all antibody species
  2. Chemical release of payload (DTT reduction for disulfide; acidic hydrolysis for hydrazone; enzymatic digestion for NCL ADCs)
  3. LC-MS/MS quantitation of released payload with stable-label IS
  4. Result = conjugated payload per mL of plasma → can convert to cAb using average DAR

This approach avoids the need for anti-drug antibodies entirely. It has been validated for several clinical programs and is referenced in FDA regulatory submissions.

Challenge 2: White Paper Recommendation vs. Regulatory Guidance — Which Takes Precedence?

Problem: The AAPS 2013 paper recommends testing ≥10 individual matrix lots for selectivity, while FDA BMV 2018 requires only ≥6. A regulatory reviewer flags the method for using only 6 lots.

Answer: Regulatory guidance takes precedence. AAPS white papers are advisory, not regulatory requirements. However:

  1. Use ≥10 lots for programs seeking global approval (aligns with ICH M10 and proactively addresses EMA expectations)
  2. Document the scientific rationale for lot number choice in the validation report
  3. If ICH M10 is the applicable standard (post-2022 programs), use ≥10 lots (M10 requirement)

Challenge 3: ISR for Hybrid LBA-MS Assay — How Many Samples?

Problem: ISR for ELISA/ECL assays is well-defined (≥10% of samples, ≥67% within ±20%). For hybrid LBA-MS assays, there are no specific ICH M10 or FDA guidance criteria.

Current consensus (AAPS 2020 workshop; EBF 2022):

  • Apply the same ±20% criterion as for LBA (hybrid assay has LBA capture step introducing LBA variability)
  • Apply ≥10% of samples (same as M10)
  • Document the choice and justify that the hybrid assay meets LBA (not LC-MS/MS) criteria given the dominant source of variability is in the capture step

Graph View

Backlinks